Generic placeholder image

Current Drug Safety

Author(s): Rim Lakhmiri*, Yahia Cherrah and Samira Serragui

DOI: 10.2174/0115748863274863231222023853

DownloadDownload PDF Flyer Cite As
Tumor Necrosis Alpha (TNF-α) Antagonists Used in Chronic Inflammatory Rheumatic Diseases: Risks and their Minimization Measures

Page: [431 - 443] Pages: 13

  • * (Excluding Mailing and Handling)

Abstract

Tumor necrosis factor alpha (TNF- α) inhibitors are widely employed for the management of chronic inflammatory rheumatism. However, their usage carries significant risks, including site and infusion reactions, serious infections, malignancy, heart failure autoimmune and demyelinating disorders. These risks are comprehensively outlined in risk management plans (RMPs) associated with these molecules. RMP provides information on the safety profile of a medicinal product as well as the measures that will be taken to minimize risks; these are known as risk minimization measures. These measures are divided into routine measures related to elements, such as the summary of product characteristics, labeling, pack size, package leaflet, or legal supply status of the product, while additional measures may include educational programs, including tools for healthcare providers and patients, controlled access or pregnancy prevention programs, among others. Additional measures can consist of one or more interventions that need to be implemented in a sustainable way in a defined target group, while respecting the timing and frequency of any intervention and procedures to reach the target population. An evaluation of the effectiveness of these measures is required to determine whether or not an intervention has been effective. This comprehensive review offers an in-depth exploration of the current treatment, uses, and associated risks of TNF-α inhibitors. Additionally, it provides a detailed account of risk minimization measures and risk management practices while shedding light on their real-world implementation and effectiveness.

Graphical Abstract

[1]
Evangelatos G, Bamias G, Kitas GD, Kollias G, Sfikakis PP. The second decade of anti-TNF-a therapy in clinical practice: New lessons and future directions in the COVID-19 era. Rheumatol Int 2022; 42(9): 1493-511.
[http://dx.doi.org/10.1007/s00296-022-05136-x] [PMID: 35503130]
[2]
Jang D, Lee AH, Shin HY, et al. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. Int J Mol Sci 2021; 22(5): 2719.
[http://dx.doi.org/10.3390/ijms22052719] [PMID: 33800290]
[3]
He B, Li Y, Luo W, et al. The risk of adverse effects of TNF-α inhibitors in patients with rheumatoid arthritis: A network meta-analysis. Front Immunol 2022; 13: 814429.
[http://dx.doi.org/10.3389/fimmu.2022.814429] [PMID: 35250992]
[4]
Esslinger S, Quinn L, Sampat S, et al. Risk management plans: Reassessment of safety concerns based on Good pharmacovigilance practices module V (Revision 2)—a company experience. J Pharm Health Care Sci 2022; 8(1): 14.
[http://dx.doi.org/10.1186/s40780-022-00244-z] [PMID: 35509028]
[5]
Holm JEJ, Ruppert JG, Ramsden SD. Impact of changing regulations and the dynamic nature of european risk management plans for human medicines on the lifecycle of safety concerns. Pharmaceut Med 2022; 36(1): 33-46.
[http://dx.doi.org/10.1007/s40290-021-00414-8] [PMID: 35099785]
[6]
European Medicines Agency and Heads of Medicines Agencies. European Medicines Agency post-authorisation procedural advice for users of the centralised procedure, EMEA-H-19984/03 Rev. 104,23 july 2023. 2023. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-post-authorisation-procedural-advice-users-centralised-procedure_en.pdf (Accessed on: 22 august 2023).
[7]
Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020; 79(6): 685-99.
[http://dx.doi.org/10.1136/annrheumdis-2019-216655] [PMID: 31969328]
[8]
Gerriets V, Goyal A, Khaddour K. Tumor Necrosis Factor Inhibitors. StatPearls Publishing 2022.
[9]
Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: Past, present and future. Int Immunol 2015; 27(1): 55-62.
[http://dx.doi.org/10.1093/intimm/dxu102] [PMID: 25411043]
[10]
Mantravadi S, Ogdie A, Kraft WK. Tumor necrosis factor inhibitors in psoriatic arthritis. Expert Rev Clin Pharmacol 2017; 10(8): 899-910.
[http://dx.doi.org/10.1080/17512433.2017.1329009] [PMID: 28490202]
[11]
Liu W, Wu Y, Zhang L, et al. Efficacy and safety of TNF-α inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis. Sci Rep 2016; 6(1): 32768.
[http://dx.doi.org/10.1038/srep32768] [PMID: 27667027]
[12]
Prince FHM, Dorai Raj AK, Otten MH, et al. TNF-alpha inhibitors for juvenile idiopathic arthritis. Cochrane Libr 2018; 2018(8): CD008598.
[http://dx.doi.org/10.1002/14651858.CD008598.pub2]
[13]
Chang J. Clinical use of anti-TNF-α biological agents. Available from: https://www.racgp.org.au/getattachment/8b7b4350-1ae1-4bc9-bce7-717faa226c94/attachment.aspx (Accessed on: 25 october 2023).
[14]
Rios Rodriguez V, Poddubnyy D. Tumor necrosis factor-α (TNFα) inhibitors in the treatment of nonradiographic axial spondyloarthritis: Current evidence and place in therapy. Ther Adv Musculoskelet Dis 2017; 9(8): 197-210.
[http://dx.doi.org/10.1177/1759720X17706454] [PMID: 28835779]
[15]
Jourdain H, Hoisnard L, Sbidian E, Zureik M. TNF-alpha inhibitors biosimilar use in France: A nationwide population-based study using the French National Health Data System. Sci Rep 2022; 12(1): 19569.
[http://dx.doi.org/10.1038/s41598-022-24050-7] [PMID: 36380105]
[16]
Barcina Lacosta T, Vulto AG, Huys I, Simoens S. Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis. Front Pharmacol 2022; 13: 1031910.
[http://dx.doi.org/10.3389/fphar.2022.1031910] [PMID: 36588696]
[17]
Phan DB, Bewley AP, Smith CH, et al. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: A drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). Br J Dermatol 2023; 189(1): 62-70.
[http://dx.doi.org/10.1093/bjd/ljad107] [PMID: 37016153]
[18]
Dey M, Zhao SS, Moots RJ. Anti-TNF biosimilars in rheumatology: the end of an era? Expert Opin Biol Ther 2021; 21(1): 29-36.
[http://dx.doi.org/10.1080/14712598.2020.1802421] [PMID: 32735158]
[19]
Dipasquale V, Cucinotta U, Romano C. Biosimilars in pediatric IBD: Updated considerations for disease management. Biologics 2022; 16: 57-66.
[PMID: 35721798]
[20]
Car E, Vulto AG, Houdenhoven MV, Huys I, Simoens S. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends. Front Pharmacol 2023; 14: 1151764.
[http://dx.doi.org/10.3389/fphar.2023.1151764] [PMID: 37153785]
[21]
Food and Drug Administration. Biosimilar product information. Available from: https://www.fda.gov/drugs/biosimilars/biosimilar-product-information (Accessed on: 15 June 2023).
[22]
Santoro A, Genov G, Spooner A, Raine J, Arlett P. Promoting and protecting public health: How the European union pharmacovigilance system works. Drug Saf 2017; 40(10): 855-69.
[http://dx.doi.org/10.1007/s40264-017-0572-8] [PMID: 28735357]
[23]
European Medicines Agency and Heads of Medicines Agencies. Guidance on the format of the risk management plan (RMP) in the EU – in integrated format, EMA/164014/2018 Rev.2.0.1 accompanying GVP Module V Rev.2, 31 October 2018. 2018. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-rmp-eu-integrated-format-rev-201_en.pdf (Accessed on: 15 March 2023).
[24]
European Medicines Agency and Heads of Medicines Agencies. Guideline on good pharmacovigilance practices (GVP) Annex I – Definitions (Rev 2), EMA/876333/2011 Rev 2*,28 March 2017. 2017. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-v-risk-management-systems-rev-2_en.pdf (Accessed on: 21 March 2023).
[25]
Cobert B. Signals, risk & reporting safety issues - C3iHC BPO. HCLTech Lifesciences. C3i Solutions. 2013. Available from: https://lifesciencescare.hcltech.com/terminology-signals-potential-signals-risks-identified-risks-and-potential-risks/ (Accessed on: 18 August 2023).
[26]
Dieck GS, Sharrar RG. Preparing for safety issues following drug approval: pre-approval risk management considerations. Ther Adv Drug Saf 2013; 4(5): 220-8.
[http://dx.doi.org/10.1177/2042098613498091] [PMID: 25114783]
[27]
von Bruchhausen T, Schirp S. Risk management plans in the EU: Managing safety concerns. Available from: https://journal.emwa.org/eu-regulations/risk-management-plans-in-the-eu-managing-safety-concerns/article/6001/risk-management-plans-in-the-eu.pdf (Accessed on: 19 august 2023).
[28]
European Medicines Agency and Heads of Medicines Agencies. Explanatory Note to GVP Module VII, EMA/670256/2017 Rev. 3. 2023. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vii-periodic-safety-update-report-explanatory_en.pdf (Accessed on: 22 August 2023).
[29]
European Medicines Agency and Heads of Medicines Agencies. Summary of risk management plan for Enbrel (etanercept). Available from: https://www.ema.europa.eu/en/documents/rmp-summary/enbrel-epar-risk-management-plan-summary_en.pdf (Accessed on: 30 march 2023).
[30]
European Medicines Agency and Heads of Medicines Agencies. Summary of risk management plan for Remicade (Infliximab). Available from: https://www.ema.europa.eu/en/documents/rmp-summary/remicade-epar-risk-management-plan-summary_en.pdf(Accessed on: on 30 march 2023).
[31]
European Medicines Agency and Heads of Medicines Agencies and Abbvie. Agencies and Abbvie. Adalimumab Core Risk Management Plan Version 16.0 / Data Lock Point 31 Dec 2021. 2021. Available from: https://www.ema.europa.eu/en/documents/rmp-summary/humira-epar-risk-management-plan-summary_en.pdf (Accessed on: 30 march 2023).
[32]
European Medicines Agency and Heads of Medicines Agencies. Summary of risk management plan for Simponi (Golimumab). Available from: https://www.ema.europa.eu/en/documents/rmp-summary/simponi-epar-risk-management-plan-summary_en.pdf (Accessed on: 30 march 2023).
[33]
European Medicines Agency and Heads of Medicines Agencies. Summary of risk management plan for certolizumab pegol Available from: https://www.ema.europa.eu/en/documents/rmp-summary/cimzia-epar-risk-management-plan-summary_en.pdf
[34]
European Medicines Agency and Heads of Medicines Agencies. Guideline on good pharmacovigilance practices (GVP) Module XVI – Risk minimisation measures: selection of tools and effectiveness indicators (Rev 2), EMA/204715/2012 Rev 2*, 28 March 2017. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-xvi-risk-minimisation-measures-selection-tools_en-3.pdf (Accessed on: 21 March 2023).
[35]
Balfour H. Pharmacovigilance deep dive: Risk minimisation measures. European Pharmaceutical Review. 2022. Available from: https://www.europeanpharmaceuticalreview.com/article/174008/pharmacovigilance-deep-dive-risk-minimisation-measures/ (Accessed on: 18 May 2023).
[36]
Agyemang E, Bailey L, Talbot J. Additional risk minimisation measures for medicinal products in the European union: A review of the implementation and effectiveness of measures in the United Kingdom by one marketing authorisation holder. Pharmaceut Med 2017; 31(2): 101-12.
[http://dx.doi.org/10.1007/s40290-017-0184-8] [PMID: 28413313]
[37]
Da Silva-Tillmann B, Wilson MC, Doshi H, Lievano F, Perrott M, Renz C. Digital additional risk minimization measures: An exploratory study using qualitative feedback from healthcare professionals and patients across six countries. Pharmaceut Med 2022; 36(1): 21-32.
[http://dx.doi.org/10.1007/s40290-021-00415-7] [PMID: 35006578]
[38]
A practical approach to screening psoriasis patients for therapy with biologic agents. J Clin Aesthet Dermatol 2008; 1(3): 50-4.
[PMID: 21203363]
[39]
Forero E, Chalem M, Vásquez G, Jauregui E, Medina LF, Pinto Peñaranda LF. Risk management for prescribing biological therapies. Rev Colomb 2016; 23(1): 50-67.
[http://dx.doi.org/10.1016/j.rcreue.2016.05.003]
[40]
Haynes K, Beukelman T, Curtis JR, et al. Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune‐mediated diseases. Arthritis Rheum 2013; 65(1): 48-58.
[http://dx.doi.org/10.1002/art.37740] [PMID: 23055441]
[41]
Al-Omar HA, Sherif HM, Mayet AY. Vaccination status of patients using anti-TNF therapy and the physicians’ behavior shaping the phenomenon: Mixed-methods approach. PLoS One 2019; 14(10): e0223594.
[http://dx.doi.org/10.1371/journal.pone.0223594] [PMID: 31584996]
[42]
Simonetti O, Rizzetto G, Molinelli E, et al. Safety and efficacy of vaccines during COVID-19 pandemic in patients treated with biological drugs in a dermatological setting. Healthcare 2021; 9(4): 401.
[http://dx.doi.org/10.3390/healthcare9040401] [PMID: 33916122]
[43]
Madani AN, Al-Saif FM, Alzamil LR, et al. Monitoring the effect of TNF-alpha inhibitors on laboratory parameters and adverse effects in different diseases: A retrospective, single-center study. Ann Saudi Med 2022; 42(5): 309-18.
[http://dx.doi.org/10.5144/0256-4947.2022.309] [PMID: 36252145]
[44]
Azor R, Martín-Masot B, Khialani D, Fernández-Martín A, Fernández G, Vm N-L. Proactive monitoring of anti-TNF agents improves follow-up of paediatric patients with Crohn disease. An Pediatr 2023; 98(3): 165-74.
[45]
Adverse events reporting guidelines for healthcare professionals. Available from: https://www.dra.gov.pk/wp-content/uploads/2022/04/Adverse-Events-Reporting-Guidelines-for-Healyhcare-Professionals-Edition-01.pdf
[46]
Schneiderova K, Bere N, Stenver DI, Straus SMJM. Patient preferences for rituximab additional risk minimization measures: Results from an international online survey. J Patient Saf 2022; 18(4): 331-6.
[http://dx.doi.org/10.1097/PTS.0000000000000919] [PMID: 34608891]
[47]
World Health Organization (WHO). Good storage and distribution practices for medical products. WHO Drug Inf 2019; 33(2)
[48]
American Society of Hospital Pharmacists. ASHP guidelines: Minimum standard for pharmacies in hospitals. Am J Health Syst Pharm 2013; 70(18): 1619-30.
[http://dx.doi.org/10.2146/sp130001] [PMID: 23988605]
[49]
Barbier L, Vandenplas Y, Simoens S, Declerck P, Vulto AG, Huys I. Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians. J Pharm Policy Pract 2021; 14(1): 53.
[http://dx.doi.org/10.1186/s40545-021-00330-x] [PMID: 34158128]
[50]
Kallio S, Eskola T, Pohjanoksa-Mäntylä M, Airaksinen M. Medication risk management in routine dispensing in community pharmacies. Int J Environ Res Public Health 2020; 17(21): 8186.
[http://dx.doi.org/10.3390/ijerph17218186] [PMID: 33167543]
[51]
Toivo TM, Mikkola JAV, Laine K, Airaksinen M. Identifying high risk medications causing potential drug–drug interactions in outpatients: A prescription database study based on an online surveillance system. Res Social Adm Pharm 2016; 12(4): 559-68.
[http://dx.doi.org/10.1016/j.sapharm.2015.09.004] [PMID: 26459026]
[52]
Norwich University Online. Risk management in nursing: Career opportunities. Available from: https://online.norwich.edu/academic-programs/resources/risk-management-nursing (Accessed on: 22 August 2023).
[53]
Sandstrom SK. Nursing management of patients receiving biological therapy. Semin Oncol Nurs 1996; 12(2): 152-62.
[http://dx.doi.org/10.1016/S0749-2081(96)80009-X] [PMID: 8727802]
[54]
European Medicines Agency and Heads of Medicines Agencies. Good practice guide on risk minimisation and prevention of medication errors, 18 November 2015 EMA/606103/2014 Pharmacovigilance Risk Assessment Committee (PRAC). 2014. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/good-practice-guide-risk-minimisation-prevention-medication-errors_en.pdf (Accessed on: 30 May 2023).
[55]
Pouresmail Z, Nabavi FH, Rassouli M. The development of practice standards for patient education in nurse-led clinics: a mixed-method study. BMC Nurs 2023; 22(1): 277.
[http://dx.doi.org/10.1186/s12912-023-01444-0] [PMID: 37605142]
[56]
Vultaggio A, Perlato M, Nencini F, Vivarelli E, Maggi E, Matucci A. How to prevent and mitigate hypersensitivity reactions to biologicals induced by anti-drug antibodies? Front Immunol 2021; 12: 765747.
[http://dx.doi.org/10.3389/fimmu.2021.765747] [PMID: 34790200]
[57]
Beauvais C, Fayet F, Rousseau A, et al. Efficacy of a nurse-led patient education intervention in promoting safety skills of patients with inflammatory arthritis treated with biologics: A multicentre randomised clinical trial. RMD Open 2022; 8(1): e001828.
[http://dx.doi.org/10.1136/rmdopen-2021-001828] [PMID: 35296528]
[58]
Redmond M. Chemotherapy and biotherapy: What nurses need to know when administering to nononcologic patients. J Contin Educ Nurs 2016; 47(2): 52-4.
[http://dx.doi.org/10.3928/00220124-20160120-03] [PMID: 26840235]
[59]
Kerr J. Recognition and management of anaphylaxis CLINICAL GUIDELINE. Available from: https://mypsych.nhsggc.org.uk/media/1861/mhs-32-guidance-on-the-recognition-and-management-of-anaphylaxis.pdf (Accessed on: 25 october 2023).
[60]
Bahri P, Morales DR, Inoubli A, Dogné JM, Straus SMJM. Proposals for engaging patients and healthcare professionals in risk minimisation from an analysis of stakeholder input to the EU valproate assessment using the novel analysing stakeholder safety engagement tool (ASSET). Drug Saf 2021; 44(2): 193-209.
[http://dx.doi.org/10.1007/s40264-020-01005-3] [PMID: 33125664]
[61]
Godfrey C, Tauscher G, Hunsberger S, et al. A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries. BMC Infect Dis 2016; 16(1): 269.
[http://dx.doi.org/10.1186/s12879-016-1579-y] [PMID: 27287374]
[62]
Shivaji UN, Sharratt CL, Thomas T, et al. Review article: Managing the adverse events caused by anti‐TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2019; 49(6): 664-80.
[http://dx.doi.org/10.1111/apt.15097] [PMID: 30735257]
[63]
Klatte K, Subramaniam S, Benkert P, et al. Development of a risk-tailored approach and dashboard for efficient management and monitoring of investigator-initiated trials. BMC Med Res Methodol 2023; 23(1): 84.
[http://dx.doi.org/10.1186/s12874-023-01902-y] [PMID: 37020207]
[64]
Bartoli F, Bruni C, Cometi L, et al. Premedication prevents infusion reactions and improves retention rate during infliximab treatment. Clin Rheumatol 2016; 35(11): 2841-5.
[http://dx.doi.org/10.1007/s10067-016-3351-5] [PMID: 27436188]
[65]
Cáceres MC, Guerrero-Martín J, Pérez-Civantos D, Palomo-López P, Delgado-Mingorance JI, Durán-Gómez N. The importance of early identification of infusion-related reactions to monoclonal antibodies. Ther Clin Risk Manag 2019; 15: 965-77.
[http://dx.doi.org/10.2147/TCRM.S204909] [PMID: 31447561]
[66]
Dogra S, Khullar G. Tumor necrosis factor-α antagonists: Side effects and their management. Indian J Dermatol Venereol Leprol 2013; 79(S7): 35.
[http://dx.doi.org/10.4103/0378-6323.115526] [PMID: 23974693]
[67]
Matsui T, Umetsu R, Kato Y, et al. Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: The Food and Drug Administration adverse event reporting system, 2004-2015. Int J Med Sci 2017; 14(2): 102-9.
[http://dx.doi.org/10.7150/ijms.17025] [PMID: 28260984]
[68]
Pasadyn SR, Knabel D, Fernandez AP, Warren CB. Cutaneous adverse effects of biologic medications. Cleve Clin J Med 2020; 87(5): 288-99.
[http://dx.doi.org/10.3949/ccjm.87a.19119] [PMID: 32357984]
[69]
Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L. Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. J Crohn’s Colitis 2013; 7(10): 769-79.
[http://dx.doi.org/10.1016/j.crohns.2013.01.009] [PMID: 23453887]
[70]
De Stefano L, Pallavicini FB, Mauric E, et al. Tumor necrosis factor-α inhibitor-related autoimmune disorders. Autoimmun Rev 2023; 22(7): 103332.
[http://dx.doi.org/10.1016/j.autrev.2023.103332] [PMID: 37062440]
[71]
Ramos-Casals M, Roberto-Perez-Alvarez D-L, Diaz-Lagares C, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by biological agents. Autoimmun Rev 2010; 9(3): 188-93.
[http://dx.doi.org/10.1016/j.autrev.2009.10.003] [PMID: 19854301]
[72]
Kucharz EJ, Kotulska-Kucharz A. Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it? Reumatologia 2021; 59(2): 65-7.
[http://dx.doi.org/10.5114/reum.2021.105438] [PMID: 33976458]
[73]
Kaltsonoudis E, Zikou AK, Voulgari PV, Konitsiotis S, Argyropoulou MI, Drosos AA. Neurological adverse events in patients receiving anti-TNF therapy: A prospective imaging and electrophysiological study. Arthritis Res Ther 2014; 16(3): R125.
[http://dx.doi.org/10.1186/ar4582] [PMID: 24938855]
[74]
Kemanetzoglou E, Andreadou E. CNS Demyelination with TNF-α Blockers. Curr Neurol Neurosci Rep 2017; 17(4): 36.
[http://dx.doi.org/10.1007/s11910-017-0742-1] [PMID: 28337644]
[75]
Liao T, Li M, Yuan T, et al. Case Report: Severe thrombocytopenia induced by adalimumab in rheumatoid arthritis: A case report and literature review. Front Pharmacol 2022; 13: 1041884.
[http://dx.doi.org/10.3389/fphar.2022.1041884] [PMID: 36386149]
[76]
Rosiek A, Leksowski K. The risk factors and prevention of cardiovascular disease: The importance of electrocardiogram in the diagnosis and treatment of acute coronary syndrome. Ther Clin Risk Manag 2016; 12: 1223-9.
[http://dx.doi.org/10.2147/TCRM.S107849] [PMID: 27540297]
[77]
Cardiovascular Disease Risk: Screening With Electrocardiography. 2018. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cardiovascular-disease-risk-screening-with-electrocardiography (Accessed on: 24 octobre 2023).
[78]
Hussain A, Tarahomi T, Singh L, Bollampally M, Heydari-Kamjani M, Kesselman MM. Cardiovascular risk associated with TNF alpha inhibitor use in patients with rheumatoid arthritis. Cureus 2021; 13(9): e17938.
[http://dx.doi.org/10.7759/cureus.17938] [PMID: 34660128]
[79]
Kwon HJ, Cot TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138(10): 807-11.
[http://dx.doi.org/10.7326/0003-4819-138-10-200305200-00008] [PMID: 12755552]
[80]
Torres-Castiblanco JL, Carrillo JA, Hincapié-Urrego D, Rojas-Villarraga A. Tuberculosis in the era of anti-TNF-alpha therapy: Why does the risk still exist? Biomédica 2018; 38(1): 17-26.
[http://dx.doi.org/10.7705/biomedica.v38i0.3458] [PMID: 29668129]
[81]
Shim TS. Diagnosis and treatment of latent tuberculosis infection in patients with inflammatory bowel diseases due to initiation of anti-tumor necrosis factor therapy. Intest Res 2014; 12(1): 12-9.
[http://dx.doi.org/10.5217/ir.2014.12.1.12] [PMID: 25349559]
[82]
Gupta A, Fine SM, Vail RM, McGowan JP, Merrick ST, Radix AE. Prevention and management of hepatitis B virus infection in adults with HIV. Johns Hopkins University 2022.
[83]
Katz LH, Fraser A, Leibovici L, Tur-Kaspa R, Goldvaser H. Lamivudine for preventing reactivation of hepatitis B infection in patients planned to undergo immunosuppressive therapy. Cochrane Libr 2019; 2019(9)
[http://dx.doi.org/10.1002/14651858.CD005264.pub3]
[84]
George EF, Elena N, Mrinalini D, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2023; 82(6): 742-53.
[85]
D’Arcy ME, Beachler DC, Pfeiffer RM, et al. Tumor necrosis factor inhibitors and the risk of cancer among older Americans with rheumatoid arthritis. Cancer Epidemiol Biomarkers Prev 2021; 30(11): 2059-67.
[http://dx.doi.org/10.1158/1055-9965.EPI-21-0125] [PMID: 34426413]
[86]
Wilton KM, Matteson EL. Malignancy incidence, management, and prevention in patients with rheumatoid arthritis. Rheumatol Ther 2017; 4(2): 333-47.
[http://dx.doi.org/10.1007/s40744-017-0064-4] [PMID: 28508282]
[87]
Tarantola A, Otto MH, Armeni P, Costa F, Malandrini F, Jommi C. Early access programs for medicines: Comparative analysis among France, Italy, Spain, and UK and focus on the Italian case. J Pharm Policy Pract 2023; 16(1): 67.
[http://dx.doi.org/10.1186/s40545-023-00570-z] [PMID: 37198599]
[88]
Human Research Protection Office (HRPO). Expanded Access to Unapproved Drugs, Biologics, or Devices. Available from: https://www.hrpo.pitt.edu/policies-and-procedures/expanded-access-unapproved-drugs-biologics-or-devices (Accessed on: 22 August 2023).
[89]
Fountzilas E, Said R, Tsimberidou AM. Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits. Expert Opin Investig Drugs 2018; 27(2): 155-62.
[http://dx.doi.org/10.1080/13543784.2018.1430137] [PMID: 29353505]
[90]
Lu CY, Ritchie J, Williams K, Day R. The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia. Aust New Zealand Health Policy 2007; 4(1): 26.
[http://dx.doi.org/10.1186/1743-8462-4-26] [PMID: 18096055]
[91]
Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Care Res 2020; 72(4): 461-88.
[http://dx.doi.org/10.1002/acr.24130] [PMID: 32090466]
[92]
Romanowska-Próchnicka K, Felis-Giemza A, Olesińska M, Wojdasiewicz P, Paradowska-Gorycka A, Szukiewicz D. The role of TNF-α and anti-TNF-α agents during preconception, pregnancy, and breastfeeding. Int J Mol Sci 2021; 22(6): 2922.
[http://dx.doi.org/10.3390/ijms22062922] [PMID: 33805757]
[93]
Dai F, Hu M, Zhang Y, et al. TNF- α/anti-TNF- α drugs and its effect on pregnancy outcomes. Expert Rev Mol Med 2022; 24(e26): e26.
[http://dx.doi.org/10.1017/erm.2022.18] [PMID: 35687009]
[94]
Lichtenstein GR, Feagan BG, Mahadevan U, et al. Pregnancy outcomes reported during the 13-year TREAT registry: A descriptive report. Am J Gastroenterol 2018; 113(11): 1678-88.
[http://dx.doi.org/10.1038/s41395-018-0202-9] [PMID: 30022113]
[95]
Weber-Schoendorfer C, Oppermann M, Wacker E, et al. Pregnancy outcome after TNF‐α inhibitor therapy during the first trimester: A prospective multicentre cohort study. Br J Clin Pharmacol 2015; 80(4): 727-39.
[http://dx.doi.org/10.1111/bcp.12642] [PMID: 25808588]
[96]
Chambers CD, Johnson DL, Xu R, et al. Birth outcomes in women who have taken adalimumab in pregnancy: A prospective cohort study. PLoS One 2019; 14(10): e0223603.
[http://dx.doi.org/10.1371/journal.pone.0223603] [PMID: 31626646]
[97]
Clowse MEB, Scheuerle AE, Chambers C, et al. Pregnancy outcomes after exposure to certolizumab pegol: Updated results from a pharmacovigilance safety database. Arthritis Rheumatol 2018; 70(9): 1399-407.
[http://dx.doi.org/10.1002/art.40508] [PMID: 29623679]
[98]
Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11(3): 286-92.
[http://dx.doi.org/10.1016/j.cgh.2012.11.011] [PMID: 23200982]
[99]
Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology 2016; 151(1): 110-9.
[http://dx.doi.org/10.1053/j.gastro.2016.04.002] [PMID: 27063728]
[100]
Liu Z, Julsgaard M, Zhu X, et al. Timing of live attenuated vaccination in infants exposed to infliximab or adalimumab in utero: A prospective cohort study in 107 children. J Crohn’s Colitis 2022; 16(12): 1835-44.
[http://dx.doi.org/10.1093/ecco-jcc/jjac093] [PMID: 35779236]
[101]
Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016; 75(5): 795-810.
[http://dx.doi.org/10.1136/annrheumdis-2015-208840] [PMID: 26888948]
[102]
Vora P, Artime E, Soriano-Gabarró M, Qizilbash N, Singh V, Asiimwe A. A review of studies evaluating the effectiveness of risk minimisation measures in Europe using the European Union electronic Register of Post‐Authorization Studies. Pharmacoepidemiol Drug Saf 2018; 27(7): 695-706.
[http://dx.doi.org/10.1002/pds.4434] [PMID: 29663572]
[103]
Practical approaches to risk minimisation for medicinal products report of CIOMS working group IX. Available from: https://cioms.ch/sd7fdh93gewd882ds/jkdf79ds7dl092dq-purple-book/CIOMS_IX_Risk_minimisation_SECURED_20140811v8.pdf (Accessed 25 October 2023).
[104]
Mouchantaf R, Auth D, Moride Y, Raine J, Han SY, Smith MY. Risk management for the 21st century: Current status and future needs. Drug Saf 2021; 44(4): 409-19.
[http://dx.doi.org/10.1007/s40264-020-01033-z] [PMID: 33565024]
[105]
Alford DP, Zisblatt L, Ng P, et al. Scope of pain: An evaluation of an opioid risk evaluation and mitigation strategy continuing education program. Pain Med 2016; 17(1): 52-63.
[106]
Adibi H, Khalesi N, Ravaghi H, Jafari M, Jeddian AR. Development of an effective risk management system in a teaching hospital. J Diabetes Metab Disord 2012; 11(1): 15.
[http://dx.doi.org/10.1186/2251-6581-11-15] [PMID: 23497710]
[107]
Chan MJ, Huang YB, Wen YH, et al. Compliance with risk management plan recommendations on laboratory monitoring of antitumor necrosis factor-α therapy in clinical practice. J Formos Med Assoc 2016; 115(2): 83-93.
[http://dx.doi.org/10.1016/j.jfma.2015.09.003] [PMID: 26602834]
[108]
Al-Fadel N, Almutairi A, Aldhirgham T, Abuesba L, Alrwisan A, Alharbi F. Implementation of risk minimization measures to reduce the risk of tuberculosis among tumor necrosis factor medication users. Pharmacoepidemiol Drug Saf 2023; pds.5682..
[http://dx.doi.org/10.1002/pds.5682] [PMID: 37615200]
[109]
Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother 2013; 4(S1): S73-7.
[http://dx.doi.org/10.4103/0976-500X.120957] [PMID: 24347988]